NeurAxis (NRXS) Reports 150% Revenue Growth in Q3 2026 Driven by Improved Insurance Reimbursement
NeurAxis (NRXS) reported strong third-quarter 2026 financial results, highlighted by a 150% increase in quarterly revenue to $2 million. This growth was primarily driven by successful efforts to convert physician demand into reimbursed treatments and the addition of two large payers covering 44 million lives. The company also saw significant margin expansion, with gross margins rising to 86.6% as the patient mix shifted from discounted assistance programs toward full reimbursement. Despite the revenue surge, operating expenses rose by 200% to $8.3 million, impacted by a one-time nonrecurring stock compensation charge of $4.3 million. Cash on hand decreased to $4.5 million due to payroll tax settlements. Looking ahead, the company is focusing on expanding its sales force and conducting clinical trials for adult applications to further drive market access and utilization.
Topics: gross margin expansion insurance reimbursement market access revenue growth
Read the full article at Motley Fool
Part of the story Artmarket.com Announces Q3 2026 Revenue Growth and Upcoming Launch of AI-Driven Visual Search Tool (35 articles)